

CIRM Funded Clinical Trials

## Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)

|                               |   |
|-------------------------------|---|
| <b>Disease Area:</b>          | COVID-19                                |
| <b>Investigator:</b>          | Michael Matthay                         |
| <b>Institution:</b>           | University of California, San Francisco |
| <b>CIRM Grant:</b>            | CLIN2COVID19-11823 (Pre-Active)         |
| <b>Award Value:</b>           | \$701,049                               |
| <b>Trial Sponsor:</b>         | University of California, San Francisco |
| <b>Trial Stage:</b>           | Phase 2                                 |
| <b>Trial Status:</b>          | Recruiting                              |
| <b>Targeted Enrollment:</b>   | 120                                     |
| <b>ClinicalTrials.gov ID:</b> | NCT03818854                             |



Michael Matthay

### Details:

Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that occurs when fluid leaks into the lungs. As a result, breathing becomes difficult and oxygen cannot get into the body. ARDS is one of the most serious and lethal consequence of COVID-19.

This clinical trial will use Mesenchymal Stromal Cells (MSCs) for the treatment of ARDS, including both COVID-19 positive and COVID-19 negative patients, with the hopes of improving oxygenation.

### Design:

Phase 2B trial

### Goal:

Test safety and efficacy.

**Source URL:** <https://www.cirm.ca.gov/clinical-trial/mesenchymal-stromal-cells-ards-covid-positive-and-covid-negative>